



Major Milestone reached at Provision Center for Proton Therapy

IBA delivers first treatment room in 12 months increasing US proton therapy treatment capacity.

Knoxville, TN, USA, December 20, 2013 - The Provision Center for Proton Therapy and IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, announced today the completion and acceptance of the first treatment room at the Provision Center for Proton Therapy in Knoxville, TN, USA.

The on-site team delivered the first of the three treatment rooms on schedule and in 12 months from Building Occupancy Date, maintaining IBA's reputation for delivering high-quality products on time.

This achievement was made possible by the unrivalled know-how of IBA teams. IBA is now approaching the key milestone of 75 proton therapy rooms worldwide. To date, IBA has helped its partners treat more than 25,000 patients worldwide.

IBA will now focus on delivering the two remaining Gantry Treatment rooms that include IBA Pencil Beam Scanning (PBS). Once completed, Provision Center for Proton Therapy will be the latest of multiple IBA centers treating cancer patients with Pencil Beam Scanning, the most precise form of Proton Therapy. PBS enables Intensity Modulated Proton Therapy (IMPT), allowing clinicians to precisely target a cancerous tumor by controlling both the intensity and the spatial distribution of the dose to the millimeter.

Bill Hansen, VP of Strategic Development at Provision Center for Proton Therapy, commented: "IBA and Provision are demonstrating that a strong partnership can help bring advanced cancer care to our community on schedule. We look forward to starting treatments for patients this January. The whole Provision team is eager to bring this extraordinary cancer treatment to East Tennessee and the entire Southeast Region."

Olivier Legrain, IBA CEO added: "I am really pleased that ambitious healthcare entrepreneurs such as Provision Health Alliance / ProNova Solutions trusted IBA to bring proton therapy to their hometown in Tennessee. This partnership reflects the confidence that our customers have in us and reinforces IBA's position as the undisputed leader in proton therapy worldwide"

Beth Klein, IBA VP Sales North America, shared: "We are very pleased with the addition of the Provision Center for PT to the growth of the treatment capacity in proton therapy in the USA. To date, IBA has helped its clinical partners treat more than 25,000 cancer patients, with 5000 of those patients treated in 2013 alone. The growth in treatment capacity of the IBA installed base is exponential, thanks to our customer's confidence in selecting IBA as their secure partner. We are proud to make this extraordinary and powerful treatment ever more accessible to patients."

-----END-----



About Proton Therapy

Proton Therapy is considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, sparing healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long-term complications, thereby improving patient outcomes and quality of life.

Today, more than half of proton therapy clinical facilities worldwide are IBA systems. This includes 15 proton therapy centers in operation and 11 additional centers under development. Over 25 000 patients have been treated on IBA equipment – more than on all major competitive installations combined.

About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.

The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room solutions. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing about 1000 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

About Provision Center for Proton Therapy

Opening in January 2014, the [Provision Center for Proton Therapy](#) will be the first of its kind in Tennessee and only the second in the Southeast. The center will provide one of the most advanced cancer treatments in the world to patients in the region. Open to all credentialed physicians and health systems in the region, the Provision Center for Proton Therapy will have three treatment rooms and will be able to treat up to 1,000 cancer patients annually, and will bring in many patients from outside the area. The center brings to Knoxville an advanced cancer treatment capability that presently is available in only a handful of cities in the U.S. When completed, it will be one of only 13 in the nation.



For further information please contact:

IBA

Olivier de Sadeleer
Marketing Manager PT
+32 10 475 890
Investorrelations@iba-group.com

Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890
communication@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications

Amber Bielecka, Mary-Jane Elliott, Matthew Neal
+44 (0) 207 920 2333
IBA@consilium-comms.com

Provision Center for Proton Therapy

Gretchen Crawley
Marketing Manager
(865) 321-4554
gretchen.crawley@provisionhp.com

Bill Hansen
VP of Strategic Development
(865) 321-4568
bill.hansen@provisionproton.com